Edrecolomab is a murine monoclonal antibody targeting the cell-surface glycoprotein EpCAM (17-1A), which is expressed on epithelial tissues and on various carcinomas. Edrecolomab may be used in the adjuvant treatment of patients with resected stage III colon cancer.